Document is current
Any future updates will be listed below
-
Authors
Panet, François https://orcid.org/0000-0002-4949-2144
Papakonstantinou, Andri
Borrell, Maria
Vivancos, Joan
Vivancos, Ana
Oliveira, Mafalda https://orcid.org/0000-0001-9152-8799
-
Funding
Funding for this research was provided by:
Lady davis institute, CIUSSS du Centre-Ouest-de-l'Île-de-Montréal
Svenska Sällskapet för Medicinsk Forskning
- License Information
-
More Information
Article History
Received: 17 January 2024
Accepted: 1 June 2024
First Online: 19 June 2024
Competing interests
: F.P., A.P., M.B., and J.V. declare no financial or non-financial competing interests. A.V. reports the following advisory role: Bayer, Bristol Meyers Squibb, Guardant Health, Incyte, Roche. Stocks/Shares: Reveal Genomics. Research Grant, Institutional, Preclinical: Bristol Meyers Squibb, Incyte, Roche. M.O. reports the following advisory role: Astra Zeneca, Daiichi Sankyo/Astra Zeneca, Gilead, iTEOS, Lilly, Pierre Fabre, Relay Therapeutics, Roche, SeaGen. Steering committee: Astra Zeneca, Roche (no financial interest). Speaker or educational activities: Eisai, Gilead, Libbs, MSD, Novartis, Pfizer, Roche, Seattle Genetics. Travel grants: Astra Zeneca, Eisai, Gilead, Pierre Fabre Local PI institutional: Astra Zeneca, Ayala Pharmaceuticals, Boehringer-Ingelheim, Gilead, GSK, Roche, Seattle Genetics, Zenith Epigenetics. Coordinating PI: Astra Zeneca. Member board of directors, head: SOLTI (no financial interest).
